|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
|
DE3432714A1
(de)
|
1984-09-06 |
1986-04-24 |
Behringwerke Ag, 3550 Marburg |
Tumortherapeutikum und verfahren zu seiner herstellung
|
|
US5153118A
(en)
|
1985-12-17 |
1992-10-06 |
Eastern Virginia Medical Authority |
Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
|
|
US5055559A
(en)
|
1986-02-20 |
1991-10-08 |
Oncogen |
Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors
|
|
US5091178A
(en)
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
|
JPH0695949B2
(ja)
|
1987-09-08 |
1994-11-30 |
工業技術院長 |
ヒトＩｇＧ１型モノクローン抗体
|
|
US5688657A
(en)
|
1988-03-31 |
1997-11-18 |
International Bio-Immune Systems, Inc. |
Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
|
|
US5162504A
(en)
|
1988-06-03 |
1992-11-10 |
Cytogen Corporation |
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
|
|
FR2635008B1
(fr)
|
1988-08-05 |
1990-11-16 |
Sanofi Sa |
Agent activateur de la productivite specifique des cellules animales recombinantes a base de polyvinylpyrrolidone et milieu de culture defini le contenant
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
IL94872A
(en)
|
1989-06-30 |
1995-03-30 |
Oncogen |
Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5124471A
(en)
|
1990-03-26 |
1992-06-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Bifunctional dtpa-type ligand
|
|
US5281699A
(en)
|
1990-06-01 |
1994-01-25 |
Tanox Biosystems, Inc. |
Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
|
PT614355E
(pt)
|
1991-11-26 |
2002-07-31 |
Jenner Technologies |
Vacinas antitumorais
|
|
CA2131528C
(en)
|
1992-03-05 |
2004-07-13 |
Philip E. Thorpe |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5756825A
(en)
|
1992-09-08 |
1998-05-26 |
Safavy; Ahmad |
Hydroxamic acid-based bifunctional chelating compounds
|
|
US5489525A
(en)
|
1992-10-08 |
1996-02-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Monoclonal antibodies to prostate cells
|
|
EP1757694A3
(en)
|
1992-11-05 |
2008-02-27 |
Sloan Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7070782B1
(en)
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
AU686660B2
(en)
|
1993-08-11 |
1998-02-12 |
Jenner Technologies |
Prostatic cancer vaccine
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
US6569432B1
(en)
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US5935818A
(en)
|
1995-02-24 |
1999-08-10 |
Sloan-Kettering Institute For Cancer Research |
Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
|
|
EP0690452A3
(en)
|
1994-06-28 |
1999-01-07 |
Advanced Micro Devices, Inc. |
Electrically erasable memory and method of erasure
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US6011021A
(en)
|
1996-06-17 |
2000-01-04 |
Guilford Pharmaceuticals Inc. |
Methods of cancer treatment using naaladase inhibitors
|
|
US7037647B1
(en)
|
1995-02-24 |
2006-05-02 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US5994292A
(en)
|
1995-05-31 |
1999-11-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
|
|
US5773292A
(en)
|
1995-06-05 |
1998-06-30 |
Cornell University |
Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
|
|
US5788963A
(en)
|
1995-07-31 |
1998-08-04 |
Pacific Northwest Cancer Foundation |
Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
|
|
US6224870B1
(en)
|
1997-01-24 |
2001-05-01 |
Genitrix, Ltd. |
Vaccine compositions and methods of modulating immune responses
|
|
US20040253246A1
(en)
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
|
US6150508A
(en)
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
IL126314A
(en)
|
1996-03-25 |
2003-07-31 |
Northwest Biotherapeutics Inc |
Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
US20010036928A1
(en)
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US5795877A
(en)
|
1996-12-31 |
1998-08-18 |
Guilford Pharmaceuticals Inc. |
Inhibitors of NAALADase enzyme activity
|
|
US5804602A
(en)
*
|
1996-06-17 |
1998-09-08 |
Guilford Pharmaceuticals Inc. |
Methods of cancer treatment using naaladase inhibitors
|
|
US5672592A
(en)
|
1996-06-17 |
1997-09-30 |
Guilford Pharmaceuticals Inc. |
Certain phosphonomethyl-pentanedioic acid derivatives thereof
|
|
US6046180A
(en)
|
1996-06-17 |
2000-04-04 |
Guilford Pharmaceuticals Inc. |
NAALADase inhibitors
|
|
TR199802638T2
(xx)
|
1996-06-17 |
1999-03-22 |
Guilford Pharmaceuticals, Inc. |
Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
|
|
US6017903A
(en)
|
1996-09-27 |
2000-01-25 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
EP2243827B2
(en)
|
1996-08-30 |
2017-11-22 |
Life Technologies Corporation |
Serum-free mammalian cell culture medium, and uses thereof
|
|
PL332413A1
(en)
|
1996-09-27 |
1999-09-13 |
Guilford Pharm Inc |
Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
|
|
CA2272407C
(en)
|
1996-12-10 |
2012-07-31 |
Sloan-Kettering Institute For Cancer Research |
Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
|
|
US20020155093A1
(en)
|
1997-02-18 |
2002-10-24 |
Houghton Alan N. |
Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
|
|
DE69832158T2
(de)
|
1997-02-25 |
2006-08-10 |
Arizona Board Of Regents, Tempe |
Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
|
|
WO1998053812A1
(en)
|
1997-05-27 |
1998-12-03 |
Guilford Pharmaceuticals Inc. |
Inhibitors of naaladase enzyme activity
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US5981209A
(en)
|
1997-12-04 |
1999-11-09 |
Guilford Pharmaceuticals Inc. |
Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
|
|
US6372955B1
(en)
*
|
1998-02-17 |
2002-04-16 |
Ortho Mcneil Pharmaceutical, Inc. |
Methods for Producing B cells and antibodies from H2-O modified transgenic mice
|
|
FR2776702B1
(fr)
|
1998-03-24 |
2000-05-05 |
Elf Exploration Prod |
Methode de conduite d'une installation de production d'hydrocarbures
|
|
US6200765B1
(en)
|
1998-05-04 |
2001-03-13 |
Pacific Northwest Cancer Foundation |
Non-invasive methods to detect prostate cancer
|
|
JP2000080100A
(ja)
*
|
1998-06-17 |
2000-03-21 |
Japan Tobacco Inc |
副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
|
|
US6395718B1
(en)
|
1998-07-06 |
2002-05-28 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
|
|
EP1093453B1
(en)
|
1998-07-06 |
2005-09-28 |
Guilford Pharmaceuticals Inc. |
Naaladase inhibitors useful as pharmaceutical compounds and compositions
|
|
IL125608A0
(en)
|
1998-07-30 |
1999-03-12 |
Yeda Res & Dev |
Tumor associated antigen peptides and use of same as anti-tumor vaccines
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
US6387888B1
(en)
|
1998-09-30 |
2002-05-14 |
American Foundation For Biological Research, Inc. |
Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
|
|
WO2000039318A1
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Compositions and methods for packaging of alphavirus vectors
|
|
US6444657B1
(en)
|
1998-12-31 |
2002-09-03 |
Guilford Pharmaceuticals Inc. |
Methods for treating certain diseases using naaladase inhibitors
|
|
US6329201B1
(en)
|
1998-12-31 |
2001-12-11 |
Chiron Corporation |
Compositions and methods for packaging of alphavirus vectors
|
|
US7074400B1
(en)
|
1999-03-01 |
2006-07-11 |
The Commonwealth Of Australia |
Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
|
|
US6897062B1
(en)
|
1999-04-09 |
2005-05-24 |
Sloan-Kettering Institute For Cancer Research |
DNA encoding the prostate-specific membrane antigen-like gene and uses thereof
|
|
WO2000061605A1
(en)
|
1999-04-09 |
2000-10-19 |
Sloan-Kettering Institute For Cancer Research |
Dna encoding the prostate-specific membrane antigen-like gene and uses thereof
|
|
EP1553414A1
(en)
|
1999-04-13 |
2005-07-13 |
Medarex, Inc. |
Methods for the diagnosis and treatment of metastatic prostate tumors
|
|
EP1175616A4
(en)
|
1999-04-13 |
2003-08-13 |
Northwest Biotherapeutics Inc |
METHOD FOR DIAGNOSIS AND TREATMENT OF METASTATIC PROSTATATORS
|
|
US6528499B1
(en)
|
2000-04-27 |
2003-03-04 |
Georgetown University |
Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
|
|
EP1208232A4
(en)
|
1999-06-10 |
2003-01-15 |
Sloan Kettering Inst Cancer |
PROSTATE CANCER MARKERS
|
|
CA2370413A1
(en)
|
1999-06-29 |
2001-01-04 |
Epimmune Inc. |
Hla binding peptides and their uses
|
|
ATE342282T1
(de)
*
|
1999-07-29 |
2006-11-15 |
Medarex Inc |
Humane monoklonale antikörper gegen prostata spezifisches membranantigen
|
|
US6313159B1
(en)
|
1999-08-20 |
2001-11-06 |
Guilford Pharmaceuticals Inc. |
Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
|
|
FR2797743B1
(fr)
|
1999-08-23 |
2003-08-08 |
Urogene |
Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
|
|
WO2001019956A2
(en)
|
1999-09-13 |
2001-03-22 |
Bander Neil H |
A method for isolation of prostatic epithelial cells from semen
|
|
AU2605501A
(en)
|
1999-12-21 |
2001-07-03 |
Epimmune, Inc. |
Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions
|
|
WO2001074845A2
(en)
|
2000-03-31 |
2001-10-11 |
Aventis Pasteur Limited |
Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
|
|
KR100643818B1
(ko)
|
2000-05-08 |
2006-11-10 |
셀덱스 쎄라퓨틱스, 인크. |
수상세포에 대한 인간 모노클로날 항체
|
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
|
JP4841794B2
(ja)
|
2000-05-12 |
2011-12-21 |
ノースウエスト バイオセラピューティクス，インコーポレイティド |
ヒト樹状細胞による外因性抗原のクラスｉ提示を増加させる方法
|
|
WO2001091738A2
(en)
|
2000-05-30 |
2001-12-06 |
Guilford Pharmaceuticals Inc. |
Naaladase inhibitors for treating amyotrophic lateral sclerosis
|
|
US6379550B1
(en)
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
|
ATE282205T1
(de)
|
2000-07-24 |
2004-11-15 |
Health Research Inc |
Verfahren zur detektion von prostata-spezifischem membran-antigen in serum
|
|
ATE536187T1
(de)
|
2000-10-19 |
2011-12-15 |
Epimmune Inc |
Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
|
|
WO2002040059A2
(en)
|
2000-11-01 |
2002-05-23 |
American Foundation For Biological Research, Inc. |
Methods and compositions for inducing cell-mediated immune responses
|
|
EP1390523B1
(en)
|
2000-11-20 |
2007-05-09 |
Eastern Virginia Medical School |
Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
EP1372736A4
(en)
|
2001-03-07 |
2004-11-17 |
Mannkind Corp |
PREPARATIONS AGAINST CANCER FORMATION
|
|
WO2003008537A2
(en)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
WO2002096460A1
(en)
|
2001-05-30 |
2002-12-05 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
|
|
JP4619651B2
(ja)
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
DE60233061D1
(de)
|
2001-09-06 |
2009-09-03 |
Alphavax Inc |
Alphavirus replikon-vektorsysteme
|
|
AU2002305767B2
(en)
|
2001-09-20 |
2008-04-10 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
US20040161776A1
(en)
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
ES2606537T3
(es)
*
|
2001-10-23 |
2017-03-24 |
Psma Development Company L.L.C. |
Anticuerpos contra PSMA
|
|
US20040018519A1
(en)
|
2001-11-16 |
2004-01-29 |
Wright ,Jr. George L |
Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
|
|
US20030157534A1
(en)
|
2001-12-26 |
2003-08-21 |
Manuel Engelhorn |
DNA immunization with libraries of minigenes encoding degenerate variants of major histocompatability class l restricted epitopes
|
|
WO2003060523A1
(en)
|
2002-01-10 |
2003-07-24 |
Johns Hopkins University |
Imaging agents and methods of imaging naaladase of psma
|
|
CN1652821A
(zh)
|
2002-01-28 |
2005-08-10 |
米德列斯公司 |
抗前列腺特异性膜抗原(psma)的人单克隆抗体
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2003219983A1
(en)
|
2002-03-01 |
2003-09-16 |
Applied Immune Technologies |
Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
|
|
CA2802205C
(en)
|
2002-07-31 |
2016-01-19 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
|
WO2006028429A2
(en)
|
2002-08-05 |
2006-03-16 |
The Johns Hopkins University |
Peptides for targeting the prostate specific membrane antigen
|
|
CN1691964A
(zh)
|
2002-09-06 |
2005-11-02 |
曼康公司 |
表位序列
|
|
TWI320716B
(en)
*
|
2002-10-14 |
2010-02-21 |
Abbott Lab |
Erythropoietin receptor binding antibodies
|
|
US20040136998A1
(en)
|
2002-10-30 |
2004-07-15 |
Bander Neil H. |
Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
|
|
EP1587837B1
(en)
|
2003-01-28 |
2012-06-13 |
Proscan RX Pharma Inc. |
Epitope sequences for prostate cancer diagnosis and treatment
|
|
WO2004067564A2
(en)
|
2003-01-29 |
2004-08-12 |
Protein Design Labs, Inc. |
Compositions against cancer antigen liv-1 and uses thereof
|
|
CA2534959A1
(en)
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
|
WO2005070456A2
(en)
|
2004-01-09 |
2005-08-04 |
Millennium Pharmaceuticals, Inc. |
Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
|
|
US8540968B2
(en)
*
|
2004-03-02 |
2013-09-24 |
Cellectar, Inc. |
Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
|
|
WO2005084390A2
(en)
|
2004-03-02 |
2005-09-15 |
Seattle Genetics, Inc. |
Partially loaded antibodies and methods of their conjugation
|
|
WO2005094882A1
(en)
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
WO2005123129A2
(en)
|
2004-06-14 |
2005-12-29 |
Regents Of The University Of California |
Methods of redistributing apical target antigens to detect and treat cellular proliferative disease
|
|
WO2006013014A2
(en)
|
2004-08-04 |
2006-02-09 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
|
|
JP2008526979A
(ja)
|
2005-01-14 |
2008-07-24 |
サイトジェン コーポレーション |
抗ｐｓｍａ抗体による併用癌治療法
|
|
WO2006089231A2
(en)
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
|
JP2008529556A
(ja)
|
2005-02-18 |
2008-08-07 |
メダレックス， インク． |
前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
|
|
WO2006093991A1
(en)
|
2005-03-02 |
2006-09-08 |
The Cleveland Clinic Foundation |
Compounds which bind psma and uses thereof
|
|
WO2006096754A2
(en)
|
2005-03-07 |
2006-09-14 |
Archemix Corp. |
Stabilized aptamers to psma and their use as prostate cancer therapeutics
|
|
WO2006110745A2
(en)
|
2005-04-08 |
2006-10-19 |
Cytogen Corporation |
Conjugated anti-psma antibodies
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
US20070160617A1
(en)
|
2005-06-20 |
2007-07-12 |
Psma Development Company, Llc |
PSMA antibody-drug conjugates
|
|
JP4945444B2
(ja)
|
2005-06-29 |
2012-06-06 |
株式会社グリーンペプタイド |
Ｈｌａ−ａ３スーパータイプアレル分子陽性前立腺癌患者に対する癌ワクチン候補となる前立腺関連蛋白由来ペプチド
|
|
US7824659B2
(en)
*
|
2005-08-10 |
2010-11-02 |
Lantheus Medical Imaging, Inc. |
Methods of making radiolabeled tracers and precursors thereof
|
|
JP5290756B2
(ja)
|
2005-09-26 |
2013-09-18 |
メダレックス インコーポレイテッド |
抗体−薬剤コンジュゲート及びその使用
|
|
US20090311225A1
(en)
|
2005-11-14 |
2009-12-17 |
Psma Development Company, Llc |
Compositions of and Methods of Using Stabilized PSMA Dimers
|
|
WO2007103288A2
(en)
|
2006-03-02 |
2007-09-13 |
Seattle Genetics, Inc. |
Engineered antibody drug conjugates
|